Liensinine Inhibits Osteosarcoma Growth by ROS-Mediated Suppression of the JAK2/STAT3 Signaling Pathway

Figure 8

Proposed model for the role of liensinine-induced ROS accumulation in the osteosarcoma treatment. Increased ROS generation can lead to oxidant and antioxidant imbalance and suppress the activation of JAK2/STAT3 pathway, promoting OS cell cycle arrest and apoptosis.